ELDN

Eledon Pharmaceuticals, Inc. [ELDN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ELDN Stock Summary

Top ELDN Correlated Resources

ELDN

Top 10 Correlated ETFs

ELDN

Top 10 Correlated Stocks

ELDN

In the News

ELDN Financial details

Company Rating
-
Market Cap
40.89M
Income
-39.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.64
Forward P/E
-
PEG
0.09
P/S
-
P/B
0.62
P/C
-
P/FCF
-1.15
Quick Ratio
20.56
Current Ratio
21.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.88
EPS next Y
-
EPS next Q
-
EPS this Y
-73.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
-18.38%
SMA50
-37.39%
SMA100
-28.54%
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-101%
ROC
-0.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.07-2.95
52W High
+49%
52W Low
+198%
RSI
38.71
Rel Volume
1.42
Avg Volume
75.82K
Volume
107.32K
Perf Week
0.34%
Perf Month
-21.37%
Perf Quarter
-15.82%
Perf Half Y
-1.65%
-
-
-
-
Beta
0.929
-
-
Volatility
0.06%, 0.31%
Prev Close
-0.33%
Price
2.98
Change
-2.61%

Something similar

Top by Market Cap
MSF.DE
FXAIX
AMZ.DE
LLY.DE
BRK-A
Top Correlated ETFs
IBB
BIB
IDNA
IBBQ
XBI
Top Correlated Stocks
CSTM
VIR
8137.HK
002920.SZ
MRAAY
Similar Market Cap
0HH6.L
TUSI
JZXN
1536.HK
KILI.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 75.82K
  • Market Capitalization 40.89M
  • Employee 20
  • CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
  • Headquarters Irvine,CA,US
  • IPO Date 2014-09-17
  • Website https://eledon.com

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.